title: Therapeutic potential of two probiotics in inflammatory bowel disease as observed in the trinitrobenzene sulfonic acid model of colitis.
abstract: OBJECTIVE
  The pathogenesis of inflammatory bowel disease is thought to be a multifactorial process. One of the leading hypotheses is that an imbalance in normal gut flora induces an excessive immune response and contributes to inflammation in the gastrointestinal tract. Administration of probiotic bacteria reduces symptoms in patients suffering from inflammatory bowel diseases, probably via both manipulation of the microflora and stimulation of the intestinal immune system. In the current study the therapeutic potential of two different probiotics-Lactobacillus GG and a mixture of Streptococcus thermophilus, Lactobacillus acidophilus, and Bifidobacterium longum (YO-MIX Y 109 FRO 1000)--in a rat model of colitis were evaluated.
  
  
  METHODS
  Male Wistar rats were administered probiotics for three days simultaneously with colitis induction. Colonic damage was evaluated histologically and biochemically and colonic tissues, as well as fecal samples, were used for bacterial studies using 16S rRNA gene primers.
  
  
  RESULTS
  Probiotics administration reduced the relative amounts of the pathogenic bacteria Aeromonas and Escherichia coli in the colonic tissue. However, whereas both probiotics affected colon morphology, only Lactobacillus GG administration reduced myeloperoxidase activity.
  
  
  CONCLUSIONS
  We report the therapeutic rather than preventive potential of two different probiotics in an animal model of colitis.
authors.affiliation: Department of Animal Science, The Faculty of Agricultural, Food and Environmental Quality Sciences, The Hebrew University of Jerusalem, Rehovot, Israel.
authors.forename: Einat
authors.initials: E
authors.lastname: Amit-Romach
authors.forename: Zehava
authors.initials: Z
authors.lastname: Uni
authors.forename: Ram
authors.initials: R
authors.lastname: Reifen
mesh_terms: D000818:Animals; D001644:Bifidobacterium; D003092:Colitis / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D004195:Disease Models, Animal; D007778:Lactobacillus; D008297:Male; D009195:Peroxidase / Q000378:metabolism; D019936:Probiotics / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D048249:Streptococcus thermophilus; D014302:Trinitrobenzenesulfonic Acid
chemical_list: D014302:Trinitrobenzenesulfonic Acid; D009195:Peroxidase